Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O95622

UPID:
ADCY5_HUMAN

ALTERNATIVE NAMES:
ATP pyrophosphate-lyase 5; Adenylate cyclase type V; Adenylyl cyclase 5

ALTERNATIVE UPACC:
O95622; B7Z8A6; Q7RTV7; Q8NFM3

BACKGROUND:
Adenylyl cyclase 5, recognized for its alternative names ATP pyrophosphate-lyase 5 and Adenylate cyclase type V, is crucial for cAMP signaling molecule formation following G-protein activation. It significantly influences the regulation of free cytosolic Ca(2+) in response to glucose levels, impacting Ca(2+)-dependent insulin release.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Adenylate cyclase type 5 could open doors to potential therapeutic strategies. Its involvement in diseases such as Dyskinesia with orofacial involvement and Neurodevelopmental disorder with hyperkinetic movements and dyskinesia highlights its potential as a target for therapeutic development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.